How to Manage Targeted Immune Suppressants (Biologics and Oral Small-molecule Drugs) Perioperatively for Inflammatory Bowel Disease and non-Inflammatory Bowel Disease surgery

Benjamin L. Cohen; Eddy Lincango; Stefan D. Holubar

doi:10.1016/j.cgh.2023.01.042

How to Manage Targeted Immune Suppressants (Biologics and Oral Small-molecule Drugs) Perioperatively for Inflammatory Bowel Disease and non-Inflammatory Bowel Disease surgery

Benjamin L. Cohen
, Eddy Lincango
, Stefan D. Holubar

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	1148-1151.e1
Journal	Clinical Gastroenterology and Hepatology
Volume	21
Issue number	5
DOIs	https://doi.org/10.1016/j.cgh.2023.01.042
State	Published - May 2023
Externally published	Yes

Access to Document

10.1016/j.cgh.2023.01.042

Cite this

@article{9c800212145148b6bdd1b09e4da9b6e9,

title = "How to Manage Targeted Immune Suppressants (Biologics and Oral Small-molecule Drugs) Perioperatively for Inflammatory Bowel Disease and non-Inflammatory Bowel Disease surgery",

author = "Cohen, \{Benjamin L.\} and Eddy Lincango and Holubar, \{Stefan D.\}",

note = "Funding Information: Conflicts of interest These authors disclose the following: Benjamin L. Cohen reports personal fees from Abbvie, Celgene-Bristol Myers Squibb, Pfizer, Sublimity Therapeutics, Janssen, Ferring, AlphaSigma, and Takeda, outside the submitted work; and non-financial support from Pfizer. Stefan D. Holubar reports personal fees from Takeda. The remaining author discloses no conflicts.",

year = "2023",

month = may,

doi = "10.1016/j.cgh.2023.01.042",

language = "English",

volume = "21",

pages = "1148--1151.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "5",

}

How to Manage Targeted Immune Suppressants (Biologics and Oral Small-molecule Drugs) Perioperatively for Inflammatory Bowel Disease and non-Inflammatory Bowel Disease surgery. / Cohen, Benjamin L.; Lincango, Eddy; Holubar, Stefan D.
In: Clinical Gastroenterology and Hepatology, Vol. 21, No. 5, 05.2023, p. 1148-1151.e1.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - How to Manage Targeted Immune Suppressants (Biologics and Oral Small-molecule Drugs) Perioperatively for Inflammatory Bowel Disease and non-Inflammatory Bowel Disease surgery

AU - Cohen, Benjamin L.

AU - Lincango, Eddy

AU - Holubar, Stefan D.

N1 - Funding Information: Conflicts of interest These authors disclose the following: Benjamin L. Cohen reports personal fees from Abbvie, Celgene-Bristol Myers Squibb, Pfizer, Sublimity Therapeutics, Janssen, Ferring, AlphaSigma, and Takeda, outside the submitted work; and non-financial support from Pfizer. Stefan D. Holubar reports personal fees from Takeda. The remaining author discloses no conflicts.

PY - 2023/5

Y1 - 2023/5

UR - https://www.scopus.com/pages/publications/85150287506

U2 - 10.1016/j.cgh.2023.01.042

DO - 10.1016/j.cgh.2023.01.042

M3 - Comment/debate

AN - SCOPUS:85150287506

SN - 1542-3565

VL - 21

SP - 1148-1151.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 5

ER -